INMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Inmune Bio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.54−0.03 (-1.91%)
Close on Oct 19, 2026
- Market cap
- $41.15M
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
Inmune Bio has not reported a dividend
No dividend per share appears in Inmune Bio's annual filings since fiscal 2016.